Navigation Links
Veridex Announces Agreement to Acquire the Assets of Immunicon Corporation
Date:6/11/2008

RARITAN, N.J., June 11 /PRNewswire-FirstCall/ -- Veridex, LLC announced today that it has signed an asset purchase agreement to acquire substantially all of the assets of Immunicon Corporation (OTC Bulletin Board: IMMC) for $31 million in cash subject to certain closing date adjustments, plus the discharge and release of certain claims owing to Veridex, LLC and the assumption of certain specified liabilities.

The assets to be acquired include intellectual property, product inventory and clinical data as well as all technologies related to the CellSearch(TM) System, the first diagnostic test to automate the detection and enumeration of circulating tumor cells (CTCs), cancer cells that detach from solid tumors and enter the blood stream. The CellSearch(TM) System is currently cleared for the prognosis and monitoring of patients with metastatic breast, metastatic colorectal and metastatic prostate cancer.

"This agreement represents a strategic opportunity for Veridex to continue to bring innovative diagnostic tests to the patients, physicians and laboratories involved in the fight against cancer," said Ken Berlin, General Manager, Veridex, LLC.

Veridex and Immunicon have partnered since 2000 to develop and commercialize novel cancer diagnostic platforms and products.

The transaction is subject to the approval by the bankruptcy court overseeing Immunicon's bankruptcy case. It is not expected to require anti-trust review or shareholder approval.

About Veridex

Veridex, LLC, a Johnson & Johnson company, is an organization dedicated to providing physicians with high-value in vitro diagnostic oncology products. Veridex is focused on developing products that will significantly benefit patients through earlier disease detection, and enable personalized medicine strategies to improve patient management and outcomes. The company develops cancer diagnostic products that may enable earlier disease detection as well as more accurate monitoring and therapeutic selection. The company is currently marketing two product lines: CellSearch(TM) assays that enumerate circulating tumor cells in blood and GeneSearch(TM) assays using molecular technology. For additional information, please visit http://www.veridex.com

(This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from Veridex's expectations and projections. Risks and uncertainties include the satisfaction of closing conditions for the acquisition, including receipt of approval for the transaction by the bankruptcy court overseeing Immunicon's bankruptcy case, and the possibility that the transaction will not be completed; general industry conditions and competition; economic conditions, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health care reforms and governmental laws and regulations; and trends toward health care cost containment. A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 30, 2007. Copies of this Form 10-K, as well as subsequent filings, are available online at http://www.sec.gov, http://www.jnj.com or on request from Johnson & Johnson. Veridex does not undertake to update any forward-looking statements as a result of new information or future events or developments.)


'/>"/>
SOURCE Veridex, LLC
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. BioSpecifics Technologies Corp. Announces Additional Sales of Stock in Private Placement Offering
2. Diffusion Pharmaceuticals Announces Addition of Mark T. Giles to its Board of Directors
3. Oncolytics Biotech Inc. Announces Start of Enrolment in Phase 1/2 Ovarian Cancer Clinical Trial with REOLYSIN(R)
4. Appature Announces onKey as an Innovative Platform for Creating Microsoft HealthVault-Compatible Applications
5. Premier Research Announces Completion of Management Buyout
6. ProMetic announces Octapharma publication of PRDTS prion removal resin in Octaplas(R) manufacturing process at 30th International Congress of the International Society for Blood Transfusion meeting in Macao SAR, China
7. Nuevolution Announces Drug Discovery Alliance With Lexicon Pharmaceuticals
8. onTargetjobs Announces Appointment of Michael Tansey as New CEO
9. Tethys Bioscience Announces Expanded Availability of PreDx(TM) Diabetes Risk Test
10. QLT announces positive Health Canada decision on Aczone(R)
11. ETHICON, INC. Announces Revised Label For REGRANEX(R) (becaplermin) Gel 0.01%
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... (PRWEB) , ... April 29, 2016 , ... Summit for ... to support the development of a patient-specific stem cell therapy for the treatment of ... lab of Dr. Jeanne Loring at The Scripps Research Institute in San Diego, CA. ...
(Date:4/29/2016)... April 29, 2016 Elekta is ... update to its industry-leading treatment planning software, is available ... Monaco version 5.11 provides significant performance ... calculation speeds up to four times faster than in ... the industry,s gold standard Monte Carlo ...
(Date:4/28/2016)... NEW YORK , April 28, 2016 /PRNewswire/ ... biotechnology acceleration company reports the Company,s CEO  was ... capital titled Accelerators Enter When VCs Fear To ... Life Science Leader magazine is an ... work for everything from emerging biotechs to Big ...
(Date:4/28/2016)... ... April 28, 2016 , ... Next week on May ... its first-in-class technologies for tissue stem cell counting and expansion to gene-editing scientists ... Reprogramming & CRISPR-based Genome Engineering in Burlington, Massachusetts. , The attention of most ...
Breaking Biology Technology:
(Date:3/18/2016)... --> --> Competitive Landscape Analysis ... Physical infrastructure and Perimeter Surveillance & Detection Systems ... and the continuing migration crisis in the Middle ... led visiongain to publish this unique report, which is crucial ... & security companies in the border security market and the ...
(Date:3/14/2016)... , Allemagne, March 14, 2016 ... http://www.apimages.com ) - --> - Renvoi : ... - --> --> ... solutions biométriques, fournit de nouveaux lecteurs d,empreintes digitales ... LF10 de DERMALOG sera utilisé pour produire des ...
(Date:3/9/2016)... March 9, 2016 This BCC Research report ... of the RNA Sequencing (RNA Seq) market for the ... instruments, tools and reagents, data analysis, and services. ... of the RNA-Sequencing market such as RNA-Sequencing tools and ... main factors affecting each segment and forecast their market ...
Breaking Biology News(10 mins):